Standard Biotools (LAB) Liabilities from Discontinued Operations (2024 - 2025)
Standard Biotools (LAB) posted quarterly Liabilities from Discontinued Operations of 25633000.0 for Q4 2025, up 23.21% year-over-year from 20804000.0 in Q4 2024, and up 15.39% quarter-over-quarter from 22214000.0 in Q3 2025.
Standard Biotools (LAB) Liabilities from Discontinued Operations (2024 - 2025) Analysis & Trends
Standard Biotools (LAB) has reported Liabilities from Discontinued Operations for 2 consecutive years, with 25633000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Liabilities from Discontinued Operations rose 23.21% year-over-year to 25633000.0; the TTM figure through Dec 2025 stood at 25633000.0 (up 23.21% YoY), while the FY2025 annual figure was 25633000.0, up 23.21% from the prior year.
- Liabilities from Discontinued Operations grew to 25633000.0 in Q4 2025 per LAB's latest filing, from 22214000.0 in the prior quarter.
- Across five years, Liabilities from Discontinued Operations topped out at 25633000.0 in Q4 2025 and bottomed at 17984000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.72 Bn | 197.12 Bn | 7.27 Bn |
| 2 | Stryker | 126.42 Bn | 122.94 Bn | 4.50 Bn |
| 3 | Medtronic | 119.75 Bn | 110.53 Bn | 6.41 Bn |
| 4 | Boston Scientific | 74.13 Bn | 73.60 Bn | 3.85 Bn |
| 5 | Edwards Lifesciences | 51.78 Bn | 47.53 Bn | 1.35 Bn |
| 6 | Dexcom | 35.29 Bn | 33.34 Bn | 830.00 Mn |
| 7 | GE HealthCare Technologies | 33.95 Bn | 31.85 Bn | 2.18 Bn |
| 8 | Koninklijke Philips | 26.22 Bn | 22.90 Bn | 4.55 Bn |
| 9 | Steris | 23.21 Bn | 22.73 Bn | 684.20 Mn |
| 10 | Standard Biotools | 260.01 Mn | -216.70 Mn | 10.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 25.63 Mn |
| Dec 31, 2025 | 25.63 Mn |
| Sep 30, 2025 | 22.21 Mn |
| Sep 30, 2025 | 22.21 Mn |
| Jun 30, 2025 | 17.98 Mn |
| Jun 30, 2025 | 17.98 Mn |
| Dec 31, 2024 | 20.80 Mn |
| Dec 31, 2024 | 20.80 Mn |